Evaluation of Safety and Efficacy of An Ayurceutical Formulation DRDC/2023/044 for Haemoglobin Levels and Iron Deficiency Anaemia - Nil

Dabur India Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年4月1日

试验速览

暂无简介。

•Males with Haemoglobin level between 12.9 g/dL and 8 g/dL 12.9 g/dL and = 8 g/dL
•Females with Haemoglobin level between 11.9 g/dL. and 8 g/dL 11.9 g/dL and = 8 g/dL
•Serum Calcium levels less than 8.5 mg/dl 8.5 mg/dl
•Not Taking any Iron or nutraceutical supplements currently or within 3 | months
•Subjects with Reported Intolerance to oral iron supplementation like constipation/ diarrhoea/eructation/ abdominal pain/nausea
•Females with regular heavier than normal menstrual periods Clinical symptoms of Anaemia, Low calcium levels
•Non pregnant & non lactating females

•Haemoglobin level less than 8 g/dL In either sex
•Females with Irregular heavier than normal menstrual periods IDA with any associated complication
•Participants who in Investigators opinion will not be able to follow study procedures. Any other type of Anaemia except IDA Prescence of any medical condition Thalassaemia, Diabetes, Hyperterision, Planning to get pregnant in near future. Patients who have a known history of severe cardiovascular disease.
•Patients with concurrent serious Hepatic dysfunction or Renal Dysfunction l or other concurrent severe disease.
•Patients who have completed participation in any other clinical trial during the last 6 months

发起方

Dabur India Pvt Ltd